Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2026
New In Situ Gel Eye Formulation Based on Aristoflex and Xanthan Gum in the Management of Glaucoma Disease: Nonclinical Studies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Biswal Snehanjana, Das Debajyoti, Sahoo Rudra Narayan, Parmanik Ankita
Аннотация
PURPOSE: Glaucoma, a class of visual neuropathies, is caused by the progressive degeneration of retinal ganglion cells, resulting in vision loss. Acetazolamide, a carbonic anhydrase inhibitor, is typically used to treat glaucoma. To minimize its harmful effects, the current study aimed to develop an acetazolamide-loaded in situ gel by combining natural polymers, such as sodium alginate and xanthan gum (XG), and cold-processable synthetic polymer Aristoflex (AF).
METHODS: Design Expert software was used to identify the optimized formulation by analyzing in vitro drug release study and viscosity data. The selected in situ gel was evaluated based on its physicochemical properties and other nonclinical evaluations.
RESULTS: Optimized formulation yielded satisfactory results in physicochemical characterizations. The drug-excipient compatibility analysis revealed no drug-polymer interactions. In vitro and ex vivo release studies showed release of up to 70% and 65%, respectively, in 6 h. The intraocular pressure of the rabbit decreased over a long period after applying the optimized gel compared with the marketed formulation.
CONCLUSION: Therefore, the research provided a brief explanation that the combination of AF and XG can be utilized in in situ gels owing to its high retention time and reduced harmful effects for ocular illnesses.
METHODS: Design Expert software was used to identify the optimized formulation by analyzing in vitro drug release study and viscosity data. The selected in situ gel was evaluated based on its physicochemical properties and other nonclinical evaluations.
RESULTS: Optimized formulation yielded satisfactory results in physicochemical characterizations. The drug-excipient compatibility analysis revealed no drug-polymer interactions. In vitro and ex vivo release studies showed release of up to 70% and 65%, respectively, in 6 h. The intraocular pressure of the rabbit decreased over a long period after applying the optimized gel compared with the marketed formulation.
CONCLUSION: Therefore, the research provided a brief explanation that the combination of AF and XG can be utilized in in situ gels owing to its high retention time and reduced harmful effects for ocular illnesses.